Pharma R&D Annual Review 2017

CLICK HERE FOR MORE INFO

REQUEST A DEMO

FIND OUT MORE HERE

Pharma, like the movies, is getting bigger and bolder, growing by pretty much every measure in 2016. Here is our quick guide to the most important plots, twists and actors in today’s biopharmaceutical marketplace.

Pharma R&D Annual Review 2016

WHAT A PERFORMANCE!

14,872 8.4%

pipeline projects in 2017

increase on corresponding figure from 2016

increase through 2015–16and 8.8% the previous year11.5%

The 2016 Global Pipeline

Preclin Phase I Phase II Phase III Pre-reg Registered Launched Suspended

6861

7493

1856

2064

2261

2357 95

4

197

220

102

116

1273

1395

70 79

1025

The 2017 pipeline by phaseBaby boom leads the way, but growth throughout the family

Preclinical

INCREASE INCREASE INCREASE

Phase III

INCREASEin projects

(up by 632 drugs) in projects

(up by 208 drugs) in projects

(up by 96 drugs) in projects

(up by 71 drugs)

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

15000

8000

0

2016 2017

Distribution of R&D CompaniesWhere Is The Action Taking Place?

2

3

4

5

6

7

8

9

10

GlaxoSmithKline 250 (242)

Pfizer 232 (217)

Merck & Co. 229 (223)

Johnson & Johnson 214 (227)

AstraZeneca 213 (231)

Roche 206 (211)

Sanofi 193 (199)

Bristol-Myers Squibb 144 (136)

Takeda 141 (137)

Novartis sits at the top of the tree. The Swiss conglomerate’s ascendancy to pole position is compounded by the fact that it originated a greater proportion of its pipeline itself compared to GSK.No. of Drugs in Pipeline 2017 (2016): 251(240)

47% 3% Germany3% France6% UK

19%Asian firms now accountfor 19% of companies, up from 16% last year, and driven not only by further expansion in China, but also by general growth throughout the region.

Asia companies up from16% a year ago

USA Down 1%from 2016

R&D Activity

1

11.1%

Anticancer

Biotechnology

Neurological

Anti-Infective

Reformulations

Alimentary/Metabolic

Musculoskeletal

Cardiovascular

Immunological

Dermatological

Sensory

Blood & Clotting

Genitourinary

Hormonal

Antiparasitic

4176

25132542

22212468

20802132

19992149

14991574

950962

869917

831911

855845

725797

608

597630

254275

121128

652

4845

40514481

2016 2017

16.0%INCREASE

Drugs in the pipelinewith a cancer focus

32.6%Drugs in development that have an oncological target

Anti-infectives

GROWTH

Anticancer, other2231 Projects

Anticancer, immunological2001 Projects

TOP TWO THERAPIES BASED ON PHARMAPROJECTS CATEGORIES

As biologicals proliferate, is the small molecule becoming a dinosaur?

In synthetic chemicals(Small molecules)

1

2

3

4

5

6

7

8

9

Chemical, synthetics

Origin

Biological, protein, antibody

Biological, protein, recombinant

Biological, protein

Chemical, synthetic, peptide

Biological, virus particles

Biological, cellular

Biological, nucleic acid, viral vector

Chemical, synthetic, nucleic acid

10 Biological, cellular, autologous

7,855 (7,540)

No of Active drugs 2017 (2016)

1,687 (1,466)

861 (892)

545 (439)

468 (434)

367 (303)

352 (210)

329 (297)

323 (301)

251 (214)

4.2%INCREASE

Monoclonal antibody-based drugs

15.1%INCREASE

The industry is involved in transferring a significant proportion of its eggs

into the biotech basket.

BIOTECH-DERIVED DRUGSNOW APPEAR IN OVER ATHIRD OF R&D ACTIVITY

RISE IN NUMBERS OF DRUGS RECEIVING ORPHAN DRUG STATUSOR AN EXPEDITED REVIEW DESIGNATION 2014–2016

2014 2015 2016

There were slightly fewer orphan drug statuses granted than during the previous year.

Orphan Drug Status Granted Expedited Review Status Granted

326 394 182 369 188

As the curtain falls on another year of pharma

IN THE LIMELIGHTTop 25 Therapies

157

1 2

Top 10 PharmaCompanies

BY SIZE OF PIPELINE

Top 10 Origins ofPipeline Drugs

BY NUMBER OF ACTIVE DRUGS

Big beasts still dominate, but Novartis is the new king of the jungle

USA

Rest of Europe

Rest of Asia Pacific

China

UK

Canada

Japan

Germany

France

C & S America/Africa

Respiratory

47%

11%

5%

3%

16%

6%

5%

3% 3% 1%

48%

9%

4%

3%

2%

18%

5%

5%

3% 3%

2016 2017

16% The Rest of Europe

Darwinian forces mean pharma’s creatures must find their niches

So it would seem that, for yet another year, the take-home message on pharma R&Dcan be summed up most simply as: there’s more of it than ever.

Survival of the fittest

Phase II

Top Companies

The pharma forest is teeming with lifeTotal R&D pipeline size16,000

14,000

12,000

10,000

8,000

6,000

4,000

2,000

02001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

Source: Pharmaprojects®, January 2017

Pharma R&D By Numbers

Welcome to Pharmaprojects’ 2017 review of trends in pharmaceutical R&D

9.2% 11.2% 7.4% 4.2%

Types of pipeline drugs

Phase I